Exxonmobil Investment Management Inc. TX Trims Holdings in Alexion Pharmaceuticals, Inc. (ALXN)

Exxonmobil Investment Management Inc. TX trimmed its holdings in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 12.8% during the fourth quarter, Holdings Channel reports. The fund owned 35,523 shares of the biopharmaceutical company’s stock after selling 5,234 shares during the quarter. Exxonmobil Investment Management Inc. TX’s holdings in Alexion Pharmaceuticals were worth $4,248,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Fiduciary Trust Co. acquired a new position in shares of Alexion Pharmaceuticals in the 2nd quarter worth approximately $111,000. Valeo Financial Advisors LLC acquired a new position in shares of Alexion Pharmaceuticals in the 3rd quarter worth approximately $147,000. Dupont Capital Management Corp acquired a new position in shares of Alexion Pharmaceuticals in the 3rd quarter worth approximately $156,000. BT Investment Management Ltd acquired a new position in shares of Alexion Pharmaceuticals in the 3rd quarter worth approximately $165,000. Finally, YorkBridge Wealth Partners LLC lifted its position in shares of Alexion Pharmaceuticals by 221.7% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 1,425 shares of the biopharmaceutical company’s stock worth $173,000 after purchasing an additional 982 shares during the period. 94.26% of the stock is currently owned by hedge funds and other institutional investors.

Alexion Pharmaceuticals, Inc. (ALXN) opened at $122.48 on Friday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.51 and a current ratio of 2.96. Alexion Pharmaceuticals, Inc. has a 1 year low of $96.18 and a 1 year high of $149.34. The stock has a market cap of $27,360.00, a price-to-earnings ratio of 54.68, a P/E/G ratio of 1.03 and a beta of 1.17.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a net margin of 9.08% and a return on equity of 3.51%. The company had revenue of $859.00 million for the quarter, compared to the consensus estimate of $864.34 million. During the same quarter in the previous year, the company earned $1.23 EPS. Alexion Pharmaceuticals’s quarterly revenue was up 7.5% compared to the same quarter last year. research analysts expect that Alexion Pharmaceuticals, Inc. will post 4.82 earnings per share for the current fiscal year.

In related news, CEO Ludwig Hantson sold 2,553 shares of the business’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total transaction of $310,521.39. Following the transaction, the chief executive officer now owns 36,172 shares in the company, valued at approximately $4,399,600.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.35% of the stock is owned by insiders.

ALXN has been the topic of a number of recent analyst reports. Royal Bank of Canada initiated coverage on shares of Alexion Pharmaceuticals in a research report on Thursday, September 14th. They issued an “outperform” rating and a $161.00 price target on the stock. Leerink Swann restated a “buy” rating and issued a $182.00 price target on shares of Alexion Pharmaceuticals in a research report on Monday, September 25th. Zacks Investment Research downgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, October 2nd. Piper Jaffray Companies restated an “overweight” rating and issued a $170.00 price target on shares of Alexion Pharmaceuticals in a research report on Monday, October 23rd. Finally, Stifel Nicolaus dropped their price target on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating on the stock in a research report on Tuesday, October 24th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and nineteen have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $154.00.

TRADEMARK VIOLATION WARNING: “Exxonmobil Investment Management Inc. TX Trims Holdings in Alexion Pharmaceuticals, Inc. (ALXN)” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.com-unik.info/2018/01/12/exxonmobil-investment-management-inc-tx-trims-holdings-in-alexion-pharmaceuticals-inc-alxn.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit